1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8
Shareholders Approve Amendment to 2019 Equity Incentive Plan
Announces First Quarter 2026 Financial Results and Provides Corporate Update
Financial Results, Press Release
CARDAMYST™: First FDA-Approved, Self-Administered Treatment for PSVT
Other Events
Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Receives FDA Approval of CARDAMYST™
Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload